Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$40.3M
47M shares
52-week range
$0.63 – $2.57
12% from low
Sector
SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
Exchange
NASDAQ
CS
InspireMD Inc is a United States-based medical device company. It is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The products of the company are the CGuard carotid Embolic Prevention System (CGuard EPS) and the MGuard Prime Embolic Protection System. It generates the majority of the revenue from the sales of CGuard EPS, which combines MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. The Company has one operating and reporting segment that develops, manufactures, and markets products for the treatment of carotid artery disease and other vascular diseases, including the Company's proprietary CGuard stent platform.
www.inspiremd.comNo one on the platform currently holds NSPR.
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 17,609 | $28.7K |
| Execution date | Ratio |
|---|---|
| 2021-04-27 | 1-for-15reverse |
| 2019-04-01 | 1-for-50reverse |
| 2018-02-08 | 1-for-35reverse |
| 2016-10-11 | 1-for-25reverse |
| 2015-10-01 | 1-for-10reverse |
No one on the platform has traded NSPR yet.
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.
$NSPR This looks like it wants to get back above a dollar
View on StockTwits ↗$NSPR Big boy tutes are holding or buying more 👀 https://fintel.io/so/us/nspr All eyes on tomorrow for 10-Q and Monday for earnings call tied with recommercialization.
View on StockTwits ↗$NSPR .86 is next resistance then should gap to .90 and above 1 shortly after 👀
View on StockTwits ↗$NSPR Currently trading at a market cap equivalent to their cash at hand. This means that all sales and enterprise value is NOT being considered! Two giant values completely absent from the valuation that are close to clearing: - U.S. commercialization, representing historically $1.5-2.5 mil per quarter when it was FIRST introduced! Expected to be announced in LESS THAN 1 WEEK! - TCAR indication on CGuard. TCAR is currently a MONOPOLY held by Boston Scientific where they paid over $1billion to acquire the technology! TCAR indication will be a massive shakeup to the market. Expected to be announced in the next 3 months! Related to their operating capital issue - cash and burn rate continues to be an issue. HOWEVER, they have about $18 mil in funding occuring in the next 3-4 months. This will carry them into 2027 where they will continue to gain enterprise value. If any of the above milestones fails, we are cooked. But if not, slingshot guaranteed. High risk, higher reward!
View on StockTwits ↗$NSPR They will file their 10-Q on friday this week after market. It is the final date of the SEC deadline to file. It isn't going to look great - no U.S. sales and over 1 mil in product recalls. Eyes on: burn rate over that quarter and international sales. However, on Monday we should get a ton of great news / updates: - CGuard recommercialization - solidified TCAR indication timeline - CGuardians 3 update - adios Gleason 👋 hello Kathy 🙏 - cash runway - clarity on recent board and exec departures - new CGuard deliver system timeline All of this SHOULD send us naturally above 1 dollar and back to compliance. They drop nasdaq compliance news, rally until Q4, drop TCAR news, rally into 2027, drop CGuard delivery system updates and finish CGuardians 3 trial enrollment with prelim data disclosed, then... sell 👏the 👏 company 👏
View on StockTwits ↗$NSPR Monday, August 17 morning earnings call. Premarket, early week earnings to me means recommercialization is on! It would line up with the rally today, too. 🙏🙏
View on StockTwits ↗$NSPR I found something weird - maybe interesting? Insightful? InspireMD has a live and actively pursued trademark for "Garrison Medical". Last update was 7/31/2026. The trademark is described as: "Aneurism therapy system, namely, flow diverters in the nature of medical stents" Could this be something coming out of or from Adnan Siddiqui's research and trial on CGuard being used for aneurisms? Please share your thoughts! Trademarks filings are not my expertise. Source: https://tmsearch.uspto.gov/search/search-results/98241584
View on StockTwits ↗$NSPR Talked to the FDA on Friday. Got the feel we are very close to getting the legacy delivery system approved. Like very soon.
View on StockTwits ↗$NSPR does anyone read when they announce Inducement Grants? Wtf kind of vesting cycle is that. We’re going to let someone vest 96,666 shares after 5 months of employment and then the same amount in 2027 and then 40,000 shares for 2028 & 2029. Also an additional 125,000 shares each year in August for 3 years starting in 2027. Just take our money and burn it….
View on StockTwits ↗$NSPR awards inducement stock grants to a new non-executive employee under Nasdaq Rule 5635(c)(4). https://www.rapidticker.com/news/nspr-inspiremd-announces-inducement-grants-under-46fb3f
View on StockTwits ↗$NSPR It appears that they are pushing earnings out to tie it together with CGuard re-commercialization news. Then they are able to provide once again full year 2026 revenue guidance, something you typically don't do in a separate PR after an earnings call. They also know the revenue on the earnings will not be great, but this is 100% priced in, imo. We should be back above $1 in September at the latest with TCAR news on the horizon.
View on StockTwits ↗$NSPR Institutions filing 13Fs showing either holding or buying more. Little to no money moving out. Board slimmed down. C-suite reduced to only 2 executive positions - CFO and CEO. Earnings still unannounced despite occurring this week last year. Wording on most recent hiring announcement shows that commercialization and TCAR indication is imminent.
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $10M | +22.8% | $-0.74 | $-0.91–$-0.62 | — | 1 |
| 2027 | $22M | +111.2% | $-0.61 | $-0.75–$-0.52 | — | 2 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 5 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-05-04 | $-0.19 | $-0.16 | +15.8% |
| 2026-03-18 | $-0.22 | $-0.14 | +36.4% |
| 2025-11-04 | $-0.17 | $-0.17 | +0.0% |
| 2025-08-04 | $-0.24 | $-0.26 | -8.3% |
| 2025-05-09 | $-0.17 | $-0.22 | -29.4% |
| 2025-03-12 | $-0.20 | $-0.19 | +5.0% |
| 2024-11-12 | $-0.20 | $-0.16 | +20.0% |
| 2024-08-06 | $-0.19 | $-0.22 | -15.8% |
| $76M |
| — |
| IMAImageneBio Inc | $5.80 | -1.20% | $65M | — |
| MBOTMicrobot Medical Inc. | $1.63 | -2.98% | $74M | — |
Source: Financial Modeling Prep · peers by sector/industry